Published in J Natl Cancer Inst on February 07, 2007
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med (2012) 3.62
Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol (2012) 2.05
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med (2012) 1.85
Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ (2009) 1.73
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer (2009) 1.46
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer (2009) 1.38
Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med (2014) 1.35
Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer (2009) 1.31
Declaration of transparency for each research article. BMJ (2013) 1.27
Knowledge integration in cancer: current landscape and future prospects. Cancer Epidemiol Biomarkers Prev (2012) 1.19
Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement. PLoS Med (2011) 1.09
Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Eur J Epidemiol (2011) 1.04
Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med (2012) 0.97
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Epidemiol (2011) 0.94
Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. BMJ (2011) 0.87
Guidelines for development of diagnostic markers in bladder cancer. World J Urol (2008) 0.86
p53 status and its prognostic role in extrahepatic bile duct cancer: a meta-analysis of published studies. Dig Dis Sci (2010) 0.83
Overview of data-synthesis in systematic reviews of studies on outcome prediction models. BMC Med Res Methodol (2013) 0.82
Health, human rights, and the conduct of clinical research within oppressed populations. Global Health (2007) 0.81
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur J Hum Genet (2011) 0.79
The reproducibility of biomedical research: Sleepers awake! Biomol Detect Quantif (2015) 0.79
S100 calcium binding protein B as a biomarker of delirium duration in the intensive care unit - an exploratory analysis. Int J Gen Med (2013) 0.78
Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Eur J Hum Genet (2011) 0.78
RiGoR: reporting guidelines to address common sources of bias in risk model development. Biomark Res (2015) 0.76
Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer (2016) 0.75
Science in the UK - whereto now? Biomol Detect Quantif (2016) 0.75
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci (2013) 13.37
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
The case of the misleading funnel plot. BMJ (2006) 8.26
Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ (2014) 7.21
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol (2008) 5.88
Research grants: Conform and be funded. Nature (2012) 5.83
Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA (2002) 5.81
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Assessment of claims of improved prediction beyond the Framingham risk score. JAMA (2009) 5.36
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Why current publication practices may distort science. PLoS Med (2008) 5.09
Evaluation of networks of randomized trials. Stat Methods Med Res (2007) 4.70
Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet (2003) 4.58
Number of published systematic reviews and global burden of disease: database analysis. BMJ (2003) 4.53
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005) 4.48
Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol (2005) 4.45
Public availability of published research data in high-impact journals. PLoS One (2011) 4.41
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Relative citation impact of various study designs in the health sciences. JAMA (2005) 4.19
Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ (2012) 4.16
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol (2010) 4.10
The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol (2010) 4.04
Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Hum Genet (2007) 3.92
Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med (2011) 3.81
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ (2002) 3.78
Translation of highly promising basic science research into clinical applications. Am J Med (2003) 3.74
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Overlapping meta-analyses on the same topic: survey of published studies. BMJ (2013) 3.57
Empirical evaluation of very large treatment effects of medical interventions. JAMA (2012) 3.48
Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet (2012) 3.48
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials (2010) 3.45
Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst (2005) 3.41
Meta-analysis in genome-wide association studies. Pharmacogenomics (2009) 3.39
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol (2004) 3.28
Medicine. Life cycle of translational research for medical interventions. Science (2008) 3.12
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst (2006) 2.91
HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics (2005) 2.81
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med (2009) 2.80
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics (2004) 2.60
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol (2005) 2.59
Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet (2013) 2.58
Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ (2009) 2.57
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ (2013) 2.52
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. Intensive Care Med (2014) 2.51
Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ (2006) 2.47
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum (2009) 2.47
Claims of sex differences: an empirical assessment in genetic associations. JAMA (2007) 2.46
Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer (2007) 2.46
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. Int J Epidemiol (2012) 2.42
Sources of funding for Nobel Prize-winning work: public or private? FASEB J (2010) 2.42
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ (2006) 2.40
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39
18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst (2008) 2.32
International ranking systems for universities and institutions: a critical appraisal. BMC Med (2007) 2.31
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol (2008) 2.31
Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int (2004) 2.30
A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst (2008) 2.29
How to use an article reporting a multiple treatment comparison meta-analysis. JAMA (2012) 2.28
STrengthening the Reporting of OBservational studies in Epidemiology--Molecular Epidemiology STROBE-ME: an extension of the STROBE statement. J Clin Epidemiol (2011) 2.24
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet (2005) 2.21
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol (2007) 2.19
A nutrient-wide association study on blood pressure. Circulation (2012) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. PLoS Med (2005) 2.18
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst (2008) 2.15
What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int J Epidemiol (2011) 2.13
Modern health care as a game theory problem. Eur J Clin Invest (2015) 2.09
Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation (2005) 2.06
Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ (2013) 2.06
US studies may overestimate effect sizes in softer research. Proc Natl Acad Sci U S A (2013) 2.06
A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum (2010) 2.02
Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet (2011) 1.98
Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ (2011) 1.97
Exploring the geometry of treatment networks. Ann Intern Med (2008) 1.95
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol (2006) 1.92
Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. Eur Heart J (2010) 1.91
Persistence of contradicted claims in the literature. JAMA (2007) 1.90